Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

[1]  P. Ascierto,et al.  Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. , 2012, The Lancet. Oncology.

[2]  C. Ng,et al.  NRAS mutation status is an independent prognostic factor in metastatic melanoma , 2012, Cancer.

[3]  S. Patel,et al.  Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases , 2012, Melanoma research.

[4]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[5]  G. Linette,et al.  A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma. , 2012 .

[6]  M. Brown,et al.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial , 2012, The Lancet.

[7]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[8]  Lauren E Haydu,et al.  Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma , 2012, Clinical Cancer Research.

[9]  G. Long,et al.  Treatment of Melanoma Brain Metastases: A New Paradigm , 2012, Cancer journal.

[10]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[11]  J. Helterbrand,et al.  Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. , 2011, European journal of cancer.

[12]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[13]  R. Jain,et al.  The biology of brain metastases—translation to new therapies , 2011, Nature Reviews Clinical Oncology.

[14]  P. Chu,et al.  Frequency of mutations associated with targeted therapy in malignant melanoma patients. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Dummer,et al.  An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Gounder,et al.  Inclusion of Patients with Brain Metastases in Phase I Trials: An Unmet Need , 2011, Clinical Cancer Research.

[17]  D. Schadendorf,et al.  Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma , 2011, Cancer.

[18]  P. Hwu,et al.  Prognostic factors for survival in melanoma patients with brain metastases , 2011, Cancer.

[19]  G. Mann,et al.  Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  John H. Sampson,et al.  A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors , 2011, PloS one.

[21]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[22]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[23]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[24]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[25]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Waterson,et al.  Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B‐RafV600E mutation , 2009 .

[27]  M. Bilsky,et al.  Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. , 2008, Neuro-oncology.

[28]  R. Millikan,et al.  Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma , 2007, Cancer Epidemiology Biomarkers & Prevention.

[29]  M. Gore,et al.  Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  K. Shannon,et al.  Determinants of outcome in melanoma patients with cerebral metastases. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Hauschild,et al.  A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma , 2003, Melanoma research.

[32]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.